Zenas BioPharma, Inc. Share Price & Technical Analysis
ZBIO · $18.96 (-0.05%)
Healthcare / Biotechnology
$18.96
-0.05%
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 3 years shown)
-1% return in May, -18% avg return in past 3 year May month.
-33% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -49% | 44% | -21% | -5% | -1% | – | – | – | – | – | – | – | -33% |
| 25 | -4% | -9% | 13% | 49% | -18% | 2% | 64% | 4% | 37% | 41% | 24% | -5% | 198% |
| 24 | – | – | – | – | – | – | – | – | -8% | 25% | -46% | -29% | -58% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.23B
P/E ratio
—
52W high
$44.60
52W low
$8.91
Volume
1,54,666
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Zenas BioPharma, Inc. share price today?
- Zenas BioPharma, Inc. (ZBIO) last traded around $18.96 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZBIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZBIO. Download the app for real-time alerts.
- How can I analyze Zenas BioPharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.